Business
Contract to Deploy Biosensors in Clinical Trial
Contract to Deploy Biosensors in Clinical Trial.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 6394W IXICO plc 16 November 2017 \n\n16 November 2017\n \nIXICO plc\n(\"IXICO\" or the \"Company\")\n \nIXICO signs its first contract with a new biopharma customer to deploy biosensors in a late stage clinical trial for a psychiatric disorder\n \nFurther expansion of IXICO's biopharma customer base and wearable biosensor technology\n \nIXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract with another leading biopharmaceutical company to support the use of wrist worn activity sensors ('wearable biosensors') in a late stage trial for a psychiatric disorder.\n \nThis contract with a new biopharma customer has a value c. £0.75m over a two year term, commencing in November 2017. IXICO will utilise its biosensor capabilities, combined with its artificial intelligence data analytics algorithms, to measure sleep, day time napping, overall daily activity levels and patterns using data collected from c.200 people at multiple time points. Furthermore, the study will allow the exploratory digital measures of patient quality of life to be evaluated alongside standard clinical measures.\n \nBetter measurement of day and night time sleep is of increasing interest in clinical research and clinical practice. For some diseases, it provides a measure of disease progression. Disrupted sleep or daytime somnolence could also represent a side effect of the medication. This could result in poor medication adherence or concerns around patient safety. Current methods of measuring sleep, daytime activity and somnolence typically rely on patient diaries or the use of rating scales. Continuous data collection using wearable biosensors has the potential to create more objective and real world measures of sleep and movement, in a specific context of use, as required by regulatory authorities.\n \nThis is IXICO's second commercial agreement involving wearable biosensors and follows on from a contract announced on 4 October 2017 to measure sleep disturbance from biosensor data collected from people with a neurological disorder.\n \nGiulio Cerroni, CEO of IXICO, commented: \"We are delighted to announce this first contract with a new biopharma customer, providing our wearable biosensor capabilities and technology to support t...